

You Can Make New FSGS Treatments Possible

CLINICAL TRIALS FOR FSGS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (ENROLLMENT COMPLETE) (Travere)	FSGS	8-75	Sparsentan	≥ 30
THE TRACTION-2 STUDY (Goldfinch Bio)	FSGS, treatment-resistant MCD, Diabetic Nephropathy	18-75	GFB-887	≥ 45
THE PODO TRIAL (Pfizer)	FSGS	18+	PF-06730512	≥ 30
ACTHAR FOR TREATMENT OF POST-TRANSPLANT FSGS (COMING SOON) (Mallinckrodt)	Recurrent FSGS	18+	Acthar	UPCR > 1 gram/day
STUDY OF VX-147 IN ADULTS WITH APOL1-MEDIATED FSGS (Vertex)	APOL1-Mediated FSGS	18-65	VX-147	≥ 30
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (COMING SOON) (Boehringer Ingelheim)	FSGS, IgAN, MN	18+	BI 685509	≥ 20 & < 90
AFFINITY (Chinook)	FSGS, IgAN, Alport Syndrome, DKD, Diabetic Nephropathy	18+	Atrasentan	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0-75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
ACTION (AUSTRALIA - ACTIVE, NOT RECRUITING) (Dimerix)	FSGS	18-80	Propagermanium	≥ 25
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



NEPHCURE
Kidney International

This is a living document and was last updated on 4/30/21

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New MCD Treatments Possible

CLINICAL TRIALS FOR MCD PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE TRACTION-2 STUDY (Goldfinch Bio)	Treatment-resistant MCD, FSGS, Diabetic Nephropathy	18-75	GFB-887	≥ 45
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

You Can Make New IgAN Treatments Possible

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PROTECT (Travere)	IgAN	18+	Sparsentan	≥ 30
SPARTAN (LEICESTER) (Travere)	IgAN	18+	Sparsentan	≥ 30
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (COMING SOON) (Boehringer Ingelheim)	IgAN, FSGS, MN	18+	BI 685509	≥ 20 & < 90
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
AFFINITY (Chinook)	IgAN, FSGS, Alport Syndrome, DKD, Diabetic Nephropathy	18+	Atrasentan	≥ 30
ALIGN (Chinook)	IgAN	18+	Atrasentan	≥ 30
SAFETY & TOLERABILITY OF BION-1301 IN HEALTHY VOLUNTEERS & ADULTS WITH IGAN (CALIFORNIA, EL PASO TEXAS, LONDON) (Chinook)	IgAN	18+	BION-1301	> 45
THE ARTEMIS-IGAN STUDY (Omeros)	IgAN	18+	OMS721	≥ 30
STUDY OF CEMDISIRAN IN ADULTS WITH IGAN (Alnylam)	IgAN	18–65	Cemdisiran	≥ 30
NEFIGARD (Calliditas)	IgAN	18+	Nefecon	≥ 45
STUDY OF RAVULIZUMAB IN IGAN & PROLIFERATIVE LUPUS NEPHRITIS (Alexion)	IgAN, Lupus Nephritis	18-75	Ravulizumab	≥ 30
SAFETY & EFFICACY OF LNP023 IN ADULTS WITH KIDNEY DISEASE CAUSED BY INFLAMMATION (ACTIVE, NOT RECRUITING) (Novartis)	IgAN	18+	LNP023	≥ 30
SAFETY & EFFICACY OF VIS649 FOR IGAN (Visterra)	IgAN	18+	VIS649	≥ 45
EFFECTIVENESS & SAFETY OF IONIS-FB-LRX IN IGAN (AUSTRALIA, CANADA, NEW ZEALAND) (Ionis)	IgAN	18–75	IONIS-FB-LRx	> 40
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.



This is a living document and was last updated on 4/30/21.

See next page for more Transplant and CKD Trials.

You Can Make New IgAN Treatments Possible

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

Trial Table updated monthly at [NephCure.org/TrialTable](https://www.NephCure.org/TrialTable)

You Can Make New Membranous Nephropathy Treatments Possible

CLINICAL TRIALS FOR MEMBRANOUS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (COMING SOON) (Boehringer Ingelheim)	MN, FSGS, IgAN	18+	BI 685509	≥ 20 & < 90
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	MN, IgAN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
M-PLACE (MorphoSys)	MN	18-80	MOR202	≥ 30
NEW-PLACE (MorphoSys)	MN	18-80	MOR202	≥ 30
REBOOT (GlaxoSmithKline)	MN	18-75	Belimumab, Rituximab	≥ 40
EFFICACY & SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN ADULTS WITH IDIOPATHIC MN (Novartis)	MN	18+	LNP023	≥ 45
EFFICACY & SAFETY OF OBINUTUZUMAB IN PARTICIPANTS WITH PRIMARY MN (COMING SOON) (Hoffmann-La Roche)	MN	18-75	Obinutuzumab	≥ 40
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New C3G Treatments Possible

CLINICAL TRIALS FOR C3G PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	C3G, Dense Deposit Disease, IgAN, MN, or Lupus Nephritis	18+	APL-2	≥ 30
THE NOBLE STUDY (Apellis)	C3G or IC-MPGN that has recurred after kidney transplant	18+	Pegcetacoplan	≥ 30
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3G, C3GN, or IC-MPGN	17–65	Ach-0144471	≤ 75
EFFICACY & SAFETY OF LNP023 IN C3G PATIENTS TRANSPLANTED & NOT TRANSPLANTED (ACTIVE, NOT RECRUITING) (Novartis)	C3G	18–65	LNP023	≥ 30
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New C3GN Treatments Possible

CLINICAL TRIALS FOR C3GN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3GN, C3G, or IC-MPGN	17-65	Ach-0144471	≤ 75
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New MPGN Treatments Possible

CLINICAL TRIALS FOR MPGN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE NOBLE STUDY (Apellis)	IC-MPGN that has recurred after kidney transplant or C3G	18+	Pegcetacoplan	≥ 30
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	IC-MPGN, C3G, or C3GN	17-65	Ach-0144471	≤ 75
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New Treatments Possible

CLINICAL TRIALS FOR TRANSPLANT PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0-75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New Treatments Possible

CLINICAL TRIALS FOR PEDIATRIC PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (ENROLLMENT COMPLETE) (Travere)	FSGS	8-75	Sparsentan	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0-75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3G, C3GN, or IC-MPGN	17-65	Ach-0144471	≤ 75

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE[®]
Kidney International

Trial Table updated monthly at [NephCure.org/TrialTable](https://www.NephCure.org/TrialTable)